ProfileGDS5678 / 1437325_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 81% 79% 82% 85% 81% 74% 80% 80% 79% 79% 80% 78% 80% 81% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.7687681
GSM967853U87-EV human glioblastoma xenograft - Control 25.57179
GSM967854U87-EV human glioblastoma xenograft - Control 35.9516782
GSM967855U87-EV human glioblastoma xenograft - Control 46.4786685
GSM967856U87-EV human glioblastoma xenograft - Control 55.7989981
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.7877274
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.5623480
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.5992480
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.4856879
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.5986479
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.6348380
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.4846478
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.7025380
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.8282681